The cytoplasmic NPM mutant induces myeloproliferation in a transgenic mouse model

Blood

Volumn 115, Issue 16, 2010, Pages 3341-3345

  Cheng, Ke ^a   Sportoletti, Paolo ^a   Ito, Keisuke ^a   Clohessy, John G ^a   Teruya Feldstein, Julie ^b   Kutok, Jeffery L ^c   Pandolfi, Pier Paolo ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN A; MESSENGER RNA; MUTANT PROTEIN; NUCLEOPHOSMIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; CYTOPLASM; GENE EXPRESSION; GENE MUTATION; HEMATOPOIESIS; HUMAN; IN VIVO STUDY; LEUKEMOGENESIS; MOUSE; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SPLEEN; TRANSGENIC MOUSE; WILD TYPE;

EID: 77951443641     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-03-208587     Document Type: Article

References (16)

1. Grisendi S, Mecucci C, Falini B, Pandolfi PP. Nucleophosmin and cancer. Nat Rev Cancer. 2006;6(7):493-505.
2. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352(3):254-266. (Pubitemid 40110814)
3. Falini B, Bolli N, Shan J, et al. Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. Blood. 2006;107(11):4514-4523. (Pubitemid 43801380)
4. + AML): biologic and clinical features. Blood. 2007;109(3):874-885.
5. Haferlach C, Mecucci C, Schnittger S, et al. AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biological, pathological, immunophenotypic, and prognostic features. Blood. 2009;114(14):3024-3032.
6. Colombo E, Martinelli P, Zamponi R, et al. Delocalization and destabilization of the Arf tumor suppressor by the leukemia-associated NPM mutant. Cancer Res. 2006;66(6):3044-3050.
7. den Besten W, Kuo M-L, Williams RT, et al. Myeloid leukemia-associated nucleophosmin mutants perturb p53-dependent and independent activities of the Arf tumor suppressor protein. Cell Cycle. 2005;4(11):1593-1598.
8. Gurumurthy M, Tan CH, Ng R, et al. Nucleophosmin interacts with HEXIM1 and regulates RNA polymerase II transcription. J Mol Biol. 2008;378(2):302-317.
9. Bonetti P, Davoli T, Sironi C, et al. Nucleophosmin and its AML-associated mutant regulate c-Myc turnover through Fbw7 gamma. J Cell Biol. 2008;182(1):19-26. (Pubitemid 352008617)
10. Cheng K, Grisendi S, Clohessy JG, et al. The leukemia-associated cytoplasmic nucleophosmin mutant is an oncogene with paradoxical functions: Arf inactivation and induction of cellular senescence. Oncogene. 2007;26(53):7391-7400. (Pubitemid 350158712)
11. Lagasse E, Weissman IL. bcl-2 inhibits apoptosis of neutrophils but not their engulfment by macrophages. J Exp Med. 1994;179(3):1047-1052 (Pubitemid 24065666)
12. Kogan SC, Ward JM, Anver MR, et al. Bethesda proposal for classification of nonlymphoid hematopoietic neoplasms in mice. Blood. 2002;100(1):238-245. (Pubitemid 35177453)
13. Hansen LA, Brown D, Virador V, et al. A PML-RARA transgene results in a retinoid-deficient phenotype associated with enhanced susceptibility to skin tumorigenesis. Cancer Res. 2003;63(17):5257-5265. (Pubitemid 37139839)
14. Siegenthaler G, Roulin K, Chatellard-Gruaz D, et al. A heterocomplex formed by the calcium-binding proteins MRP8 (S100A8) and MRP14 (S100A9) binds unsaturated fatty acids with high affinity. J Biol Chem. 1997;272(14):9371-9377. (Pubitemid 27154950)
15. Pasqualucci L, Liso A, Martelli MP, et al. Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: impact on WHO classification. Blood. 2006;108(13):4146-4155. (Pubitemid 44913286)
16. Bolli N, De Marco MF, Martelli MP et al. A dose-dependent tug of war involving the NPM1 leukaemic mutant, nucleophosmin, and ARF. Leukemia. 2009;23(3):501-509